phrykt

Fractyl Health, Inc. (GUTS): who owns it and who trades it

As of Nov 16, 2026, GUTS insiders reported 7 purchases worth $187K in the last 12 months. The largest buyer was William Bradley (Director), with $90K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Fractyl Health

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns GUTS

75 funds and institutions reported GUTS shares worth $65.2M at the end of Q2 2026, about 52% of the company. The largest holder is Nantahala Capital Management, LLC with 14.2%.

Funds and institutions (13F) 52%Everyone else 48%

10 largest owners, by share of the company

Nantahala Capital Management, LLC14.2%
Catalio Capital Management, LP3.9%
Vanguard Capital Management LLC3.8%
Bank of America Corp3.8%
Pale Fire Capital SE3.2%
General Catalyst Group Management, LLC3.1%
Deer Management Co. LLC3.0%
Maverick Capital Ltd2.5%
M28 Capital Management LP1.2%
BlackRock, Inc.1.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Nantahala Capital Management, LLC22.58M14.23%$17.9M+69%
Catalio Capital Management, LP6.17M3.89%$4.9M+12%
Vanguard Capital Management LLC6.10M3.84%$4.8M+10%
Bank of America Corp6.03M3.80%$4.8M+4728%
Pale Fire Capital SE5.00M3.15%$4M-16%
General Catalyst Group Management, LLC4.88M3.08%$3.9MNo change
Deer Management Co. LLC4.77M3.01%$3.8MNo change
Maverick Capital Ltd3.97M2.51%$3.2MNo change
M28 Capital Management LP1.86M1.17%$1.5MNo change
BlackRock, Inc.1.80M1.14%$1.4M-16%
Woodline Partners LP1.78M1.12%$1.4M-20%
Jane Street Group, LLC1.73M1.09%$1.4M+4261%
Silverarc Capital Management, LLC1.64M1.03%$1.3M-4%
UBS Group AG1.58M1.00%$1.3M-3%
CM Management, LLC1.40M0.88%$1.1MNo change
Geode Capital Management, LLC1.32M0.83%$1M-8%
Ikarian Capital, LLC1.10M0.69%$874KNo change
Marshall Wace, LLP1.08M0.68%$854K+34%
Logos Global Management LP1.00M0.63%$794KNo change
Brevan Howard Capital Management LP916,3210.58%$719K+294%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, GUTS insiders reported $187K of open-market purchases and $0 of sales.

Purchases, 12 months
$187K
7 trades, 5 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Sep 14, 2026
Filed Sep 16, 2026

Purchases and sales by month

$127K$127KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 14, 2026William BradleyDirectorPurchase64,516$0.62$40KForm 4
Jun 12, 2026Ajay RoyanDirectorPurchase23,000$0.85$19.6KForm 4
Jun 10, 2026William BradleyDirectorPurchase68,493$0.73$50KForm 4
Jun 10, 2026Ian SheffieldDirectorPurchase35,000$0.73$25.6KForm 4
Jun 10, 2026Harith RajagopalanCEOPurchase25,000$0.73$18.2KForm 4
Jun 8, 2026Weber Lara SmithCFOPurchase20,000$0.69$13.8KForm 4
Dec 4, 2025Harith RajagopalanCEOPurchase10,416$1.92$20KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
William BradleyDirector$90K–Sep 14, 2026
Harith RajagopalanChief Executive Officer, Director$38.2K–Jun 10, 2026
Ian SheffieldDirector$25.6K–Jun 10, 2026
Ajay RoyanDirector$19.6K–Jun 12, 2026
Weber Lara SmithChief Financial Officer$13.8K–Jun 8, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

GUTS short interest

Low short interest. 0.4% of GUTS shares are sold short: about 1 share in 272. Over the last 12 reports the number of shares short went down 81%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 585,071 GUTS shares were sold short, 0.4% of the shares outstanding, up 120.4% from the report before. At the average daily volume of 1.93M shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.37%May 15Oct 302.24%

Days to cover

1.0May 15Oct 303.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026585,0710.37%+120%1.93M1.0
Oct 15, 2026265,3110.17%-88%218,6341.2
Sep 30, 20262.15M1.35%-20%1.79M1.2
Sep 15, 20262.70M1.69%+22%1.78M1.5
Aug 31, 20262.22M1.39%-17%1.47M1.5
Aug 14, 20262.66M1.67%-15%977,4772.7
Jul 31, 20263.12M1.97%+24%1.79M1.8
Jul 15, 20262.52M1.59%+9%1.95M1.3
Jun 30, 20262.31M1.46%-0%1.71M1.4
Jun 15, 20262.32M1.47%-4%1.62M1.4
May 29, 20262.41M1.52%-22%1.56M1.5
May 15, 20263.10M1.95%+3%2.98M1.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Fractyl Health company events

Fractyl Health filed 20 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership, listing). The latest was on Nov 6, 2026.

  1. Nov 6, 2026LeadershipThe Board of Directors of the Company increased the size of the Board from nine to ten and appointed Michael Wartell as a Class III director, with a term expiring at the Company’s 2027 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier… Filing
  2. Oct 22, 2026LeadershipRetirement of Executive Officer In connection with the workforce reduction, on October 21, 2026, Jay Caplan announced his retirement. effective October 30, 2026, from his executive roles as the Company’s President and Chief Product Officer. Filing
  3. Oct 16, 2026AnnouncementThe Company reported topline six-month results from its REMAIN-1 Pivotal Cohort, a randomized, double-blind, sham-controlled pivotal study evaluating the safety and efficacy of Revita in maintaining weight loss after GLP-1 based therapy discontinuation. Filing
  4. Oct 1, 2026RulesChanged its bylaws or articles. Filing
  5. Sep 24, 2026VoteReported shareholder vote results. Filing
  6. Sep 11, 2026ListingAs previously disclosed, on March 13, 2026, Fractyl Health, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on… Filing
  7. Aug 10, 2026ResultsReleased financial results. Filing
  8. Jul 15, 2026AnnouncementThe Company reported one-year data from its REMAIN-1 Midpoint Cohort, a blinded, sham-controlled study evaluating Revita for weight maintenance following GLP-1 drug discontinuation. Filing
  9. Jun 11, 2026VoteReported shareholder vote results. Filing
  10. Jun 4, 2026AnnouncementThe Company announced positive one-year results from its open-label REVEAL-1 Cohort in individuals with obesity who have lost at least 15% of their total body weight on a GLP-1 medication and who either need or choose to discontinue GLP-1 therapy. Filing
  11. May 12, 2026ResultsReleased financial results. Filing
  12. May 11, 2026AnnouncementShared information with investors. Filing
  13. Mar 24, 2026ResultsReleased financial results. Filing
  14. Mar 17, 2026ListingFractyl Health, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid… Filing
  15. Feb 26, 2026AnnouncementShared information with investors. Filing
  16. Jan 29, 2026AnnouncementThe Company reported 6-month data from its REMAIN-1 Midpoint Cohort, a blinded, sham-controlled study evaluating Revita ® for weight maintenance following GLP-1 drug discontinuation. Filing
  17. Jan 6, 2026LeadershipThe Board of Directors of Fractyl Health, Inc. appointed Lara Smith Weber as Chief Financial Officer, effective January 12, 2026. Filing
  18. Jan 5, 2026AnnouncementThe Company announced its strategic outlook for 2026, including anticipated clinical and regulatory milestones across its Revita and Rejuva programs and an update to its cash position and runway guidance. Filing
  19. Dec 16, 2025AnnouncementThe Company provided notice to the holders of its outstanding Tranche A Common Stock Purchase Warrants to purchase shares of the Company’s common stock, par value $0.00001 per share that it has achieved the performance targets to call such warrants for cancellation, and will cancel the Tranche A… Filing
  20. Dec 2, 2025AnnouncementThe Company issued a press release announcing positive 6-month data from the open-label REVEAL-1 Cohort. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Fractyl Health financials

Famous investors that hold GUTS

4 of the 50 well-known investors we track reported holding GUTS in their latest 13F filing. The largest position is Lee Ainslie's, worth $2.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Lee Ainslie · Maverick CapitalQ3 20263.97M$2.2M0.0%No change
Ken Griffin · Citadel AdvisorsQ3 2026342,814$187K0.0%New
Israel Englander · Millennium ManagementQ3 2026242,275$132K0.0%New
Jim Simons · Renaissance TechnologiesQ3 2026208,505$114K0.0%+71%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named GUTS in the last 120 days.

FiledHolderFormStake
Nov 13, 2026Nantahala Capital Management, LLC13G/A6.9%
Nov 13, 2026Nantahala Capital Management, LLC13G/A6.9%
Oct 13, 2026Catalio Capital Management, LP13G5.6%
Oct 13, 2026Catalio Capital Management, LP13G5.6%

Questions about Fractyl Health, Inc. (GUTS) stock

Who owns the most GUTS stock?

The largest reported owner of Fractyl Health, Inc. (GUTS) is Nantahala Capital Management, LLC, with 14.2% of the company. In total, 75 funds and institutions reported holding GUTS at the end of Q2 2026, together about 52% of the shares. See the largest owners.

Are GUTS insiders buying or selling?

In the last 12 months, GUTS insiders reported 7 open-market purchases worth $187K and no sales. The latest trade was on Sep 14, 2026. See every trade.

What is the short interest in GUTS?

As of Oct 30, 2026, 585,071 GUTS shares were sold short, 0.4% of the shares outstanding, up 120.4% from the report before. At the average daily volume of 1.93M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold GUTS?

4 of the 50 well-known investors we track reported GUTS in their latest 13F filing, including Lee Ainslie, Ken Griffin, Israel Englander. The largest position is worth $2.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.